Q-omics provides the consensus-scored LCNL1 profile across patient tissues and cancer cell-line models. LCNL1 expression is associated with patient survival in 19 of 34 cancer types, with the highest sampling consensus in HNSC. Among the 18 cancer types available for tumor–normal comparison, LCNL1 is differentially expressed in 10, with the highest sampling consensus in KIRP. Additionally, LCNL1 RNA expression shows 17,946 significant protein co-abundance associations, with the highest sampling consensus in LSCC. Together, these results highlight HNSC, KIRP, and LSCC as cancer lineages where LCNL1 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for LCNL1 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes LCNL1 survival associations across molecular data types. LCNL1 RNA expression shows survival associations in the most cancer types (19), followed by mutation status (4). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible LCNL1 RNA expression–survival associations across cancer types. High LCNL1 expression shows unfavorable associations in KIRC, LUSC and OV, but favorable associations in HNSC, ESCA and LUAD. The HNSC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify HNSC as the clearest survival context for LCNL1 RNA expression.
This table summarizes LCNL1 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 10. The strongest signals are observed in KIRP for RNA.
This table ranks reproducible tumor–normal expression differences for LCNL1. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. LCNL1 shows lower tumor expression in KIRP, LUSC, BRCA, LUAD and KICH and higher tumor expression in COAD. The KIRP box plot shows higher LCNL1 RNA expression in normal versus tumor tissue (log2 FC = −0.267, t-test p < 0.001).
This table shows molecular features associated with LCNL1 in patient tissues and cancer cell lines. In patient samples, LCNL1 shows the broadest associations at the RNA and protein expression levels, with LSCC recurring as the lineage with the largest associated feature set. In cancer cell lines, LCNL1 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in UPPER_AERODIGESTIVE_TRACT, while CRISPR and shRNA rows add functional-dependency signals in SKIN and SOFT_TISSUE.
